<DOC>
	<DOCNO>NCT00436033</DOCNO>
	<brief_summary>Investigation efficacy safety treatment milnacipran treatment fibromyalgia syndrome .</brief_summary>
	<brief_title>A Multicentre Trial Determine Efficacy Safety Milnacipran Treatment Fibromyalgia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>patient diagnosis fibromyalgia accord 1990 American College Rheumatology ( ACR ) criterion psychiatric illness depression generalise anxiety disorder suicidal risk substance abuse active cardiac disease pulmonary dysfunction liver disease renal impairment autoimmune disease chronic inflammatory rheumatoid disease current systemic infection epileptic active cancer sleep apnea active peptic ulcer inflammatory bowel disease unstable endocrine disease men : prostatic enlargement genitourinary disorder woman : pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>